Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests.
暂无分享,去创建一个
[1] Y. Arad,et al. Prediction of coronary events with electron beam computed tomography. , 2000, Journal of the American College of Cardiology.
[2] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[3] Philip Greenland,et al. Prevention Conference V Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Executive Summary , 2000 .
[4] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .
[5] V. Fuster,et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. , 2000, Circulation.
[6] C. Hennekens. Update on aspirin in the treatment and prevention of cardiovascular disease. , 1999, American heart journal.
[7] S. Blair,et al. Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men. , 2000, The American journal of cardiology.
[8] M. Kornitzer,et al. Multifactorial Approach to the Prevention of Coronary Heart Disease: From Computer to Paper and Pencil? , 2000, Journal of cardiovascular risk.
[9] S. Grundy,et al. Problems on the pathway from risk assessment to risk reduction. , 1998, Circulation.
[10] P. Ridker. Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks? , 1999, Annals of Internal Medicine.
[11] L. Prosser,et al. Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics , 2000, Annals of Internal Medicine.
[12] V. Froelicher,et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: tests for silent and inducible ischemia: Writing Group II. , 2000, Circulation.
[13] P. Lapuerta,et al. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS). , 2000, The American journal of cardiology.
[14] A. Dyer,et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. , 1999, JAMA.
[15] R. McMahon,et al. Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. , 1989, Journal of the American College of Cardiology.
[16] G. Mancia,et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.
[17] R. Myerburg,et al. Sudden Cardiac Death: Epidemiology, Transient Risk, and Intervention Assessment , 1993, Annals of Internal Medicine.
[18] J. Cutler,et al. Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. , 1986, Journal of the American College of Cardiology.
[19] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[20] R. Weinshilboum,et al. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.
[21] L. Coupal,et al. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.
[22] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[23] P. Serruys,et al. I like the candy, I hate the wrapper: the (32)P radioactive stent. , 2000, Circulation.
[24] C. Ballantyne,et al. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. , 2000, Archives of internal medicine.
[25] S. Grundy. Primary prevention of coronary heart disease: integrating risk assessment with intervention. , 1999, Circulation.
[26] S. Grundy,et al. Cholesterol Lowering in the Elderly Population , 1999 .
[27] V. Fuster,et al. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Journal of the American College of Cardiology.
[28] S M Grundy,et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Circulation.
[29] V. Fuster,et al. Preventing heart attack and death in patients with coronary disease. , 1995, Circulation.
[30] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[31] Philip Greenland,et al. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations , 1999 .
[32] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[33] S. Grundy,et al. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. , 2000, Circulation.
[34] S. Grundy,et al. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. , 1999, Archives of internal medicine.
[35] R. Langer,et al. Mortality over a period of 10 years in patients with peripheral arterial disease. , 1992, The New England journal of medicine.
[36] R. Kronmal,et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.
[37] R. D'Agostino,et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. , 2000, Circulation.
[38] A. Folsom,et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. , 1997, American journal of epidemiology.
[39] A. Wierzbicki,et al. A Comparison of Algorithms for Initiation of Lipid Lowering Therapy in Primary Prevention of Coronary Heart Disease , 2000, Journal of Cardiovascular Risk.
[40] R H Selzer,et al. The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.
[41] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.